These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34690787)

  • 1. Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study.
    Budimirovic DB; Dominick KC; Gabis LV; Adams M; Adera M; Huang L; Ventola P; Tartaglia NR; Berry-Kravis E
    Front Pharmacol; 2021; 12():757825. PubMed ID: 34690787
    [No Abstract]   [Full Text] [Related]  

  • 2. Gaboxadol Normalizes Behavioral Abnormalities in a Mouse Model of Fragile X Syndrome.
    Cogram P; Deacon RMJ; Warner-Schmidt JL; von Schimmelmann MJ; Abrahams BS; During MJ
    Front Behav Neurosci; 2019; 13():141. PubMed ID: 31293404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The STARS Phase 2 Study: A Randomized Controlled Trial of Gaboxadol in Angelman Syndrome.
    Bird LM; Ochoa-Lubinoff C; Tan WH; Heimer G; Melmed RD; Rakhit A; Visootsak J; During MJ; Holcroft C; Burdine RD; Kolevzon A; Thibert RL
    Neurology; 2021 Feb; 96(7):e1024-e1035. PubMed ID: 33443117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX).
    Berry-Kravis E; Hagerman R; Budimirovic D; Erickson C; Heussler H; Tartaglia N; Cohen J; Tassone F; Dobbins T; Merikle E; Sebree T; Tich N; Palumbo JM; O'Quinn S
    J Neurodev Disord; 2022 Nov; 14(1):56. PubMed ID: 36434514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome.
    Heussler H; Cohen J; Silove N; Tich N; Bonn-Miller MO; Du W; O'Neill C; Sebree T
    J Neurodev Disord; 2019 Aug; 11(1):16. PubMed ID: 31370779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of the GABAergic pathway for the treatment of fragile X syndrome.
    Lozano R; Hare EB; Hagerman RJ
    Neuropsychiatr Dis Treat; 2014; 10():1769-79. PubMed ID: 25258535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arbaclofen in fragile X syndrome: results of phase 3 trials.
    Berry-Kravis E; Hagerman R; Visootsak J; Budimirovic D; Kaufmann WE; Cherubini M; Zarevics P; Walton-Bowen K; Wang P; Bear MF; Carpenter RL
    J Neurodev Disord; 2017; 9():3. PubMed ID: 28616094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.
    Lozano R; Martinez-Cerdeno V; Hagerman RJ
    Curr Pharm Des; 2015; 21(34):4972-4979. PubMed ID: 26365141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials.
    Berry-Kravis E; Des Portes V; Hagerman R; Jacquemont S; Charles P; Visootsak J; Brinkman M; Rerat K; Koumaras B; Zhu L; Barth GM; Jaecklin T; Apostol G; von Raison F
    Sci Transl Med; 2016 Jan; 8(321):321ra5. PubMed ID: 26764156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results.
    Youssef EA; Berry-Kravis E; Czech C; Hagerman RJ; Hessl D; Wong CY; Rabbia M; Deptula D; John A; Kinch R; Drewitt P; Lindemann L; Marcinowski M; Langland R; Horn C; Fontoura P; Santarelli L; Quiroz JA;
    Neuropsychopharmacology; 2018 Feb; 43(3):503-512. PubMed ID: 28816242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double Genetic Hit: Fragile X Syndrome and Partial Deletion of Protein Patched Homolog 1 Antisense as Cause of Severe Autism Spectrum Disorder.
    Saldarriaga W; Payán-Gómez C; González-Teshima LY; Rosa L; Tassone F; Hagerman RJ
    J Dev Behav Pediatr; 2020 Dec; 41(9):724-728. PubMed ID: 32947579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome.
    Sheridan SD; Theriault KM; Reis SA; Zhou F; Madison JM; Daheron L; Loring JF; Haggarty SJ
    PLoS One; 2011; 6(10):e26203. PubMed ID: 22022567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to Placebo in Fragile X Syndrome Clinical Trials: An Initial Analysis.
    Luu S; Province H; Berry-Kravis E; Hagerman R; Hessl D; Vaidya D; Lozano R; Rosselot H; Erickson C; Kaufmann WE; Budimirovic DB
    Brain Sci; 2020 Sep; 10(9):. PubMed ID: 32932789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining Lovastatin and Minocycline for the Treatment of Fragile X Syndrome: Results From the LovaMiX Clinical Trial.
    Champigny C; Morin-Parent F; Bellehumeur-Lefebvre L; Çaku A; Lepage JF; Corbin F
    Front Psychiatry; 2021; 12():762967. PubMed ID: 35058813
    [No Abstract]   [Full Text] [Related]  

  • 15. A novel combination treatment for fragile X syndrome predicted using computational methods.
    Chadwick W; Angulo-Herrera I; Cogram P; Deacon RJM; Mason DJ; Brown D; Roberts I; O'Donovan DJ; Tranfaglia MR; Guilliams T; Thompson NT
    Brain Commun; 2024; 6(1):fcad353. PubMed ID: 38226317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome.
    Ligsay A; Van Dijck A; Nguyen DV; Lozano R; Chen Y; Bickel ES; Hessl D; Schneider A; Angkustsiri K; Tassone F; Ceulemans B; Kooy RF; Hagerman RJ
    J Neurodev Disord; 2017 Aug; 9(1):26. PubMed ID: 28764646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label add-on treatment trial of minocycline in fragile X syndrome.
    Paribello C; Tao L; Folino A; Berry-Kravis E; Tranfaglia M; Ethell IM; Ethell DW
    BMC Neurol; 2010 Oct; 10():91. PubMed ID: 20937127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive training for children and adolescents with fragile X syndrome: a randomized controlled trial of Cogmed.
    Hessl D; Schweitzer JB; Nguyen DV; McLennan YA; Johnston C; Shickman R; Chen Y
    J Neurodev Disord; 2019 Apr; 11(1):4. PubMed ID: 30982467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B
    CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deficient tonic GABAergic conductance and synaptic balance in the fragile X syndrome amygdala.
    Martin BS; Corbin JG; Huntsman MM
    J Neurophysiol; 2014 Aug; 112(4):890-902. PubMed ID: 24848467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.